J&J Enters Phase 3 Trial for COVID-19 Vaccine

September 25, 2020

BioUtah member Johnson & Johnson (J&J) announced that they’ve started the global phase 3 trial of Janssen’s single-dose vaccine candidate, following phase 1/2 studies that demonstrated safety and immunogenicity. 

“As COVID-19 continues to impact the daily lives of people around the world, our goal remains the same – leveraging the global reach and scientific innovation of our company to help bring an end to this pandemic,” said Alex Gorsky, chairman and chief executive officer, Johnson & Johnson.

“This is encouraging news,” said Kelvyn Cullimore, president and CEO of BioUtah. “ We value J&J’s partnership here in Utah and applaud the dedication, science, and expertise they bring to this race for a COVID-19 vaccine.”

J&J has continued to scale up its manufacturing capacity to meet its goal of providing one billion doses of a vaccine each year and has stated that it will provide the vaccine on a not-for-profit basis.